Clinical Trial Update: Comparison of Safety and Immunogenicity of Pediacel™ and Infanrix™ IPV+Hib (Penta) Given in a 3 Dose Schedule in Infants [Phase 3]

View source ↗

Summary

Phase 3 trial comparing the safety and immunogenicity of Pediacel versus Infanrix IPV+Hib (Penta) given in a 3-dose schedule in infants; the study is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diphtheria
• Haemophilus Influenzae Type Infection
• Pertussis
• Poliomyelitis
• Tetanus

Drugs mentioned

• Infanrix IPV+Hib (Penta)
• Pediacel (Diphtheria, Tetanus, Acellular Pertussis, Inactivated Poliovirus, Haemophilus influenzae type b, Hepatitis B vaccine (DTaP-IPV-Hib-HepB))

Snippet

Sponsor: Sanofi Pasteur, a Sanofi Company | Conditions: Pertussis, Diphtheria | Phase 3 | Status: COMPLETED